<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8374">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087904</url>
  </required_header>
  <id_info>
    <org_study_id>M13-741</org_study_id>
    <secondary_id>2013-003467-60</secondary_id>
    <nct_id>NCT02087904</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study
      to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of
      ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in Pain Score of the index knee</measure>
    <time_frame>From Day 1 to Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is evaluated using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in synovitis/effusion volume of the index knee</measure>
    <time_frame>From Day 1 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is evaluated using quantitative and semiquantitative Magnetic Resonance Imaging (MRI) measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in physical function</measure>
    <time_frame>From Day 1 to Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is evaluated using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in index knee pain</measure>
    <time_frame>From Day 1 to Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is evaluated using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow lesions of the index knee</measure>
    <time_frame>From Day 1 to Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is evaluated in Magnetic Resonance Imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in index knee Intermittent and Constant Pain</measure>
    <time_frame>From Day 1 to Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is evaluated using the Intermittent and Constant Osteoarthritis Pain (ICOAP) score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Medial Compartment Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ABT-981 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-981 medium dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-981 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABT-981</intervention_name>
    <arm_group_label>ABT-981 low dose</arm_group_label>
    <arm_group_label>ABT-981 medium dose</arm_group_label>
    <arm_group_label>ABT-981 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Radiographic knee osteoarthritis with Kellgren-Lawrence Grade 2 or 3

          2. Body Mass Index (BMI) 18-34 kg/m2

          3. One or more clinical signs and symptoms of active inflammation in the index knee

        Exclusion Criteria:

          1. History of allergic reaction to any constituents of the study drug, or to any
             Immunoglobulin G (IgG)-containing product

          2. History of anaphylactic reaction to any agent

          3. Significant trauma or surgery to the index knee

        3. Severe knee malalignment 4. Any uncontrolled medical illness or an unstable treatment
        or therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne   Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret   Wojtecka</last_name>
    <phone>847-937-0494</phone>
    <email>margaret.wojtecka@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara  Gibbs</last_name>
    <phone>847-938-5302</phone>
    <email>Sara.Gibbs@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119796</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119796</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121618</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 121618</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119397</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119397</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119587</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119587</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120576</name>
      <address>
        <city>San Juan</city>
        <zip>00909-3004</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120576</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Synovitis</keyword>
  <keyword>Knee</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
